Is Pfizer Stock Poised for a Rebound? Obesity Drugs Spark Renewed Optimism

After being largely dismissed by investors due to plummeting COVID-19 revenue and looming patent expirations, pharmaceutical giant Pfizer is suddenly showing surprising signs of life. A significant catalyst has emerged from an unexpected segment: the obesity drug market. This renewed interest has prompted Guggenheim to substantially raise its price target to $35, while major institutional investors are actively increasing their holdings. Could this be the turning point for the fallen pandemic champion?

The recent surge in positive sentiment stems from Pfizer’s strategic pivot into the high-growth obesity therapeutics sector. Central to this shift is the acquisition of Metsera Inc., finalized in November. Guggenheim analysts have labeled this move Read more...